Janux Therapeutics (JANX) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Janux Therapeutics (JANX) over the past year, gaining 218.9% versus a loss of 65.0%. Nuvectis Pharma is the larger company by market cap ($666.8 million vs $616.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | NVCT |
|---|---|---|
| Share price | $10.08 | $19.39 |
| Market cap | $616.73M | $666.80M |
| 1-day change | -2.04% | -2.27% |
| YTD return | -26.96% | +156.82% |
| 1-year return | -65.00% | +218.91% |
| 5-year return | -42.92% | — |
| EPS (TTM) | $-1.59 | $-2.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.00M | — |
| Revenue growth (YoY) | -5.55% | — |
| Net income (latest FY) | $-113.63M | $-26.44M |
| Operating margin | -1576.67% | — |
| Net margin | -1136.25% | — |
| 52-week high | $35.34 | $29.28 |
| 52-week low | $10.05 | $5.77 |
| Distance from 52-week high | -71.48% | -33.77% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +228.77% | +82.57% |
| Average volume | 961.56K | 206.37K |
| Shares outstanding | 61.18M | 34.39M |
| Employees | 114 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed JANX by 283.9 percentage points over the past year.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
JANX vs NVCT FAQ
Which is bigger, Janux Therapeutics or Nuvectis Pharma?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $666.80M compared with $616.73M for Janux Therapeutics (JANX).
Which stock has performed better over the past year, JANX or NVCT?
NVCT returned +218.91% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.